Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea.
Romain GueryBenoit HenryGuillaume Martin-BlondelClaire RouzaudFlorence CordolianiGundel HarmsJean-Pierre GangneuxFrançoise FouletEmmanuelle BourratMichel BaccardGloria MorizotPaul-Henri ConsignyAntoine BerryJohannes BlumOlivier LortholaryPierre Buffetnull nullPublished in: PLoS neglected tropical diseases (2017)
In conditions close to current medical practice, the therapeutic window of L-AmB was narrow in travellers with CL or MCL, with the possible exception of those infected with L. infantum. Strict follow-up is warranted when using L-AmB in patients with mild disease.